$YMAB News
Last published 1y ago
- 1y agoYMABApproval of Danyelza, Bla #761171FDA Approved DrugsApproval Date: 08/27/2025; Drug Name: Danyelza, Bla #761171; Active Ingredients: NAXITAMAB-GQGK; Company: Y-mabs Therapeutics Inc; Submission Status: Approval; Application Number: 761171
- 1y agoYMABY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsGlobeNewswireReported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0
- 1y agoYMABY-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025GlobeNewswirePRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of
- 1y agoYMABSERB Pharmaceuticals Agrees to Acquire Y-mAbs TherapeuticsGlobeNewswireAcquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer
- 1y agoYMABY-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded PipelineGlobeNewswireCompany's Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve
- 1y agoYMABY-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research MeetingGlobeNewswirePRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of
- 1y agoYMABY-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025GlobeNewswirePRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of
- 1y agoYMABY-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate DevelopmentsGlobeNewswireReported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in
- 1y agoYMABY-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)GlobeNewswirePRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of
- 1y agoYMABY-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025GlobeNewswirePRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of
- 1y agoYMABY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireNEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaGlobeNewswireNEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswireReported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of
- 1y agoYMABY-mAbs Announces Publication of Phase 2 Interim Results in Nature CommunicationsGlobeNewswireNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025GlobeNewswireNEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences ConferenceGlobeNewswireNEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual MeetingGlobeNewswireNEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABCorrecting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 PrioritiesGlobeNewswireCompany establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase
- 1y agoYMABY-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitGlobeNewswireNEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs Provides Strategic Business Update and 2025 PrioritiesGlobeNewswireCompany establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1
- 1y agoYMABY-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoYMABY-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual MeetingGlobeNewswireNEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 1y agoYMABY-mAbs to Participate at Citi's 2024 Global Healthcare ConferenceGlobeNewswireNEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoYMABY-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswireReported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment
- 2y agoYMABY-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in JapanGlobeNewswireNEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Announces Third Quarter 2024 Conference Call and WebcastGlobeNewswireNEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs to Participate in Upcoming Investor Conferences in OctoberGlobeNewswireNEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer ResearchGlobeNewswireNEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs to Participate in Upcoming Investor Conferences in SeptemberGlobeNewswireNEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoYMABY-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswireReported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increaseContinued geographic expansion of DANYELZA with new market revenues recorded in the second
- 2y agoYMABY-mAbs to Participate in Upcoming Investor Conferences in AugustGlobeNewswireNEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Announces Second Quarter 2024 Conference Call and WebcastGlobeNewswireNEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial OfficerGlobeNewswireNEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingGlobeNewswireNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerGlobeNewswireNEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingGlobeNewswireNEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingGlobeNewswireNEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Therapeutics, Inc. (YMAB) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoYMABY-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswireReported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter
- 2y agoYMABY-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024GlobeNewswireNEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on
- 2y agoYMABY-mAbs to Present at 2024 ASCO Annual MeetingGlobeNewswireNEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Therapeutics Announces Resignation of Chief Financial OfficerGlobeNewswireNEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsGlobeNewswireNEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 2y agoYMABY-mAbs Therapeutics, Inc. (YMAB) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoYMABNBIY-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsGlobeNewswireRecord DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and cash equivalents of $78.6 million as of December 31, 2023;
- 2y agoYMABY-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024GlobeNewswireNEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its financial results for the quarter and full year ended December 31,
- 2y agoYMABY-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel